ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
|Principal Investigator's Name:||Steve Angersbach|
|Institution:||The Critical Path Institute|
|Department:||Coalition Against Major Diseases|
|Proposed Analysis:||Critical Path Institute, founded in 2005 in Tucson, Arizona, is an independent, non-profit organization dedicated to bringing scientists from the FDA, industry, and academia together to improve the path for innovative new drugs, diagnostic tests and devices to reach patients in need. The Coalition Against Major Diseases (CAMD), a consortium of Critical Path Institute, has developed a new shared and standardized database (named CODR). Currently, the database contains information from approximately 4,000 Alzheimer's subjects from eleven industry-sponsored clinical trials, and it continues to expand. The database provides the platform for qualified researchers to design more efficient clinical trials of new treatments. This will allow the industry to more rapidly identify potential therapies that have a positive effect on disease progression, and also to stop work earlier on therapies that show no benefit. With your permission, CAMD proposes to add data from the ADNI database to the currently available data in CODR. The data will be remapped to CDISC standards, loaded into our database, securely stored, and will be made available to be accessed by our qualified research members in their pursuit of improved clinical trial design and basic research. Members include pharmaceutical industry, government, academic, and healthcare professionals. We are happy to insert language in the database requesting credit be given to ADNI, as outlined in your standard agreement terms. For any questions, or if more information is desired to facilitate approval of this application, please contact Steve Angersbach, MBA, Project Manager for CAMD|